OBJECTIVE: To investigate PIK3CA mutation in Chinese patients with lung squamous cell carcinoma (LSCC) and explore their relationship with clinicopathological profiles. METHODS: Tumor samples from 123 cases of LSCC were included in this study. PIK3CA mutations in exon 9 and 20 were screened by pyrosequencing and confirmed by clone sequencing or amplification refractory mutation system (ARMS). Denaturing performance liquid chromatography (DHPLC) was employed for evaluation of EGFR mutation in exon 19, 21 and KRAS mutation. RESULTS: PIK3CA mutations were found in 3 (2.4%) patients. The mutation type included E545K, E452Q and H1047R. Of these three patients, one coupled with EGFR mutation, and the other two coupled with PIK3CA amplification. All the three patients shared the same clinicopathologic characteristics: male, less than 60 years old, had smoke history, stage III and carried wild-type KRAS. CONCLUSIONS: The frequency of PIK3CA mutation is low in Chinese patients with LSCC. The mutational status of PIK3CA is not mutually exclusive to EGFR mutation.
OBJECTIVE: To investigate PIK3CA mutation in Chinese patients with lung squamous cell carcinoma (LSCC) and explore their relationship with clinicopathological profiles. METHODS: Tumor samples from 123 cases of LSCC were included in this study. PIK3CA mutations in exon 9 and 20 were screened by pyrosequencing and confirmed by clone sequencing or amplification refractory mutation system (ARMS). Denaturing performance liquid chromatography (DHPLC) was employed for evaluation of EGFR mutation in exon 19, 21 and KRAS mutation. RESULTS:PIK3CA mutations were found in 3 (2.4%) patients. The mutation type included E545K, E452Q and H1047R. Of these three patients, one coupled with EGFR mutation, and the other two coupled with PIK3CA amplification. All the three patients shared the same clinicopathologic characteristics: male, less than 60 years old, had smoke history, stage III and carried wild-type KRAS. CONCLUSIONS: The frequency of PIK3CA mutation is low in Chinese patients with LSCC. The mutational status of PIK3CA is not mutually exclusive to EGFR mutation.
Authors: Hongbin Ji; Danan Li; Liang Chen; Takeshi Shimamura; Susumu Kobayashi; Kate McNamara; Umar Mahmood; Albert Mitchell; Yangping Sun; Ruqayyah Al-Hashem; Lucian R Chirieac; Robert Padera; Roderick T Bronson; William Kim; Pasi A Jänne; Geoffrey I Shapiro; Daniel Tenen; Bruce E Johnson; Ralph Weissleder; Norman E Sharpless; Kwok-Kin Wong Journal: Cancer Cell Date: 2006-05-25 Impact factor: 31.743
Authors: Jong Woo Lee; Young Hwa Soung; Su Young Kim; Hae Woo Lee; Won Sang Park; Suk Woo Nam; Sang Ho Kim; Jung Young Lee; Nam Jin Yoo; Sug Hyung Lee Journal: Oncogene Date: 2005-02-17 Impact factor: 9.867
Authors: Ian G Campbell; Sarah E Russell; David Y H Choong; Karen G Montgomery; Marianne L Ciavarella; Christine S F Hooi; Briony E Cristiano; Richard B Pearson; Wayne A Phillips Journal: Cancer Res Date: 2004-11-01 Impact factor: 12.701
Authors: Hiromasa Yamamoto; Hisayuki Shigematsu; Masaharu Nomura; William W Lockwood; Mitsuo Sato; Naoki Okumura; Junichi Soh; Makoto Suzuki; Ignacio I Wistuba; Kwun M Fong; Huei Lee; Shinichi Toyooka; Hiroshi Date; Wan L Lam; John D Minna; Adi F Gazdar Journal: Cancer Res Date: 2008-09-01 Impact factor: 12.701
Authors: Hua Bai; Li Mao; Hang Shu Wang; Jun Zhao; Lu Yang; Tong Tong An; Xin Wang; Chun Jian Duan; Na Mei Wu; Zhi Qing Guo; Yi Xu Liu; Hong Ning Liu; Ye Yu Wang; Jie Wang Journal: J Clin Oncol Date: 2009-05-04 Impact factor: 44.544